Multiplication of Chromosome 17 Centromere Is Associated with Prognosis in Patients with Invasive Breast Cancers Exhibiting NormalHER2andTOP2AStatus

Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer

(2010) Gottfried E. Konecny et al.   BREAST CANCER RESEARCH AND TREATMENT

Topo2α protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer

(2010) A Mukherjee et al.   BRITISH JOURNAL OF CANCER

The Comparison of Automated Silver in situ Hybridization and Fluorescence in situ Hybridization for Evaluating HER2 Gene Amplification in Breast Carcinoma

(2010) Tae-Jung Kim et al.   Journal of Breast Cancer

Comparison of Silver-Enhanced in situ Hybridization and Fluorescence in situ Hybridization for HER2 Gene Status in Breast Carcinomas

(2010) Jun Kang et al.   Journal of Breast Cancer

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer Statistics in Korea: Incidence, Mortality and Survival in 2006-2007

(2010) Kyu-Won Jung et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

Automated Silver-enhanced In Situ Hybridization for Evaluation of HER2 Gene Status in Breast Carcinoma: Comparison with Fluorescence In Situ Hybridization and Immunohistochemistry

(2010) Woo Jung Sung et al.   Korean Journal of Pathology

Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601)

(2010) John MS Bartlett et al.   LANCET ONCOLOGY

Be precise! The need to consider the mechanisms forCEP17copy number changes in breast cancer

(2009) Giuseppe Viale   JOURNAL OF PATHOLOGY

Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescencein situhybridization and microarray-based CGH analysis

(2009) Caterina Marchiò et al.   JOURNAL OF PATHOLOGY

Alterations in the TOP2A and HER2 Genes: Association With Adjuvant Anthracycline Sensitivity in Human Breast Cancers

(2009) D. J. Slamon et al.   JNCI-Journal of the National Cancer Institute

Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy

(2009) F. P. O'Malley et al.   JNCI-Journal of the National Cancer Institute

Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response

(2009) Monica M Reinholz et al.   LANCET ONCOLOGY

Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma

(2009) Uma Krishnamurti et al.   MODERN PATHOLOGY

Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event

(2009) I-Tien Yeh et al.   MODERN PATHOLOGY

Topoisomerase levels determine chemotherapy responsein vitroandin vivo

(2008) Darren J. Burgess et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials

(2007) Alessandra Gennari et al.   JNCI-Journal of the National Cancer Institute